Evolent Health (NYSE:EVH) Receives Buy Rating from BTIG Research

Key Points

• BTIG Research has reaffirmed a "Buy" rating for Evolent Health (NYSE: EVH) with a target price of $20.00, indicating a potential upside of 107.15% from the current stock price.
• Other analysts have also provided positive ratings with target prices ranging from $13.00 to $18.00, contributing to an average consensus target price of $17.43 for the stock.
• Evolent Health reported disappointing quarterly earnings with a (0.10) EPS and revenues of $444.33 million, falling short of analyst expectations and marking a 31.3% decrease year-over-year.

Evolent Health (NYSE:EVH - Get Free Report)'s stock had its "buy" rating reiterated by research analysts at BTIG Research in a research note issued on Tuesday,Benzinga reports. They currently have a $20.00 price target on the technology company's stock. BTIG Research's target price indicates a potential upside of 121.61% from the company's current price.

EVH has been the subject of several other research reports. JMP Securities restated a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a research report on Friday, June 20th. Piper Sandler raised their price objective on shares of Evolent Health from $16.00 to $18.00 and gave the company an "overweight" rating in a research report on Thursday, August 28th. Needham & Company LLC reaffirmed a "buy" rating and issued a $15.00 target price on shares of Evolent Health in a research note on Tuesday, May 13th. Finally, Truist Financial raised their target price on shares of Evolent Health from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Evolent Health has an average rating of "Buy" and a consensus price target of $17.43.

Evolent Health Price Performance

EVH traded down $0.29 during midday trading on Tuesday, hitting $9.03. The company had a trading volume of 1,376,506 shares, compared to its average volume of 3,103,884. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.01 and a current ratio of 1.01. The company has a market capitalization of $1.06 billion, a PE ratio of -5.61 and a beta of 0.73. Evolent Health has a twelve month low of $7.06 and a twelve month high of $31.80. The firm's 50-day simple moving average is $9.82 and its 200-day simple moving average is $9.50.

Evolent Health (NYSE:EVH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The company had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The company's revenue was down 31.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.30 EPS. Evolent Health has set its Q3 2025 guidance at EPS. Equities research analysts predict that Evolent Health will post 0.08 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Evolent Health by 18.6% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 36,498 shares of the technology company's stock valued at $346,000 after purchasing an additional 5,712 shares during the period. Brighton Jones LLC bought a new position in Evolent Health in the fourth quarter valued at approximately $3,927,000. Russell Investments Group Ltd. lifted its stake in Evolent Health by 28.6% in the first quarter. Russell Investments Group Ltd. now owns 98,105 shares of the technology company's stock valued at $929,000 after buying an additional 21,826 shares in the last quarter. Northern Trust Corp lifted its stake in Evolent Health by 0.7% in the first quarter. Northern Trust Corp now owns 1,203,501 shares of the technology company's stock valued at $11,397,000 after buying an additional 8,637 shares in the last quarter. Finally, Hussman Strategic Advisors Inc. lifted its stake in Evolent Health by 66.7% in the first quarter. Hussman Strategic Advisors Inc. now owns 105,000 shares of the technology company's stock valued at $994,000 after buying an additional 42,000 shares in the last quarter.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.